GURUFOCUS.COM » STOCK LIST » USA » NAS » United Therapeutics Corp (NAS:UTHR) » Definitions » Graham Number
Switch to:

United Therapeutics Graham Number

: $167.11 (As of Jun. 2022)
View and export this data going back to 1999. Start your Free Trial

Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.

As of today (2022-08-09), the stock price of United Therapeutics is $218.73. United Therapeutics's graham number for the quarter that ended in Jun. 2022 was $167.11. Therefore, United Therapeutics's Price to Graham Number ratio for today is 1.31.

The historical rank and industry rank for United Therapeutics's Graham Number or its related term are showing as below:

UTHR' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.73   Med: 1.56   Max: 6.14
Current: 1.31

During the past 13 years, the highest Price to Graham Number ratio of United Therapeutics was 6.14. The lowest was 0.73. And the median was 1.56.

UTHR's Price-to-Graham-Number is ranked better than
72.83% of 276 companies
in the Biotechnology industry
Industry Median: 2.28 vs UTHR: 1.31

Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.


United Therapeutics Graham Number Historical Data

The historical data trend for United Therapeutics's Graham Number can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Therapeutics Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Graham Number
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 99.81 134.51 - 137.42 140.15

United Therapeutics Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Graham Number Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 136.16 136.64 139.94 172.23 167.11

Competitive Comparison

For the Biotechnology subindustry, United Therapeutics's Graham Number, along with its competitors' market caps and Graham Number data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

United Therapeutics Graham Number Distribution

For the Biotechnology industry and Healthcare sector, United Therapeutics's Graham Number distribution charts can be found below:

* The bar in red indicates where United Therapeutics's Graham Number falls into.



United Therapeutics Graham Number Calculation

Graham Number is a concept based on Ben Graham's conservative valuation of companies.

United Therapeutics's Graham Number for the fiscal year that ended in Dec. 2021 is calculated as

Graham Number
=sqrt of (22.5* Tangible Book per Share *EPS without NRI)
=sqrt of (22.5*86.777*10.06)
=140.15

United Therapeutics's Graham Number for the quarter that ended in Jun. 2022 is calculated as

Graham Number
=sqrt of (22.5*Tangible Book per Share*EPS without NRI (TTM))
=sqrt of (22.5*93.95*13.21)
=167.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


United Therapeutics  (NAS:UTHR) Graham Number Explanation

Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:

Current price should not be more than 15 times average earnings of the past three years.

Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)

Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.

In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.

United Therapeutics's Price to Graham number Ratio for today is calculated as

Price to Graham number=Share Price (Today)/Graham number (Q: Jun. 2022 )
=218.73/167.11
=1.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Please keep these in mind:

1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.


United Therapeutics Graham Number Related Terms

Thank you for viewing the detailed overview of United Therapeutics's Graham Number provided by GuruFocus.com. Please click on the following links to see related term pages.


United Therapeutics Business Description

United Therapeutics logo
Traded in Other Exchanges
Address
1040 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
Executives
Benkowitz Michael officer: President and COO C/O UNITED THERAPEUTICS CORP 1040 SPRING STREET SILVER SPRING MD 20910
Maxwell Linda director 1040 SPRING STREET SILVER SPRING NC 27709
Thompson Tommy G director 7711 CARONDELET ST. LOUIS MO 63105
Mesa Nilda director C/O UNITED THERAPEUTICS CORPORATION 1040 SPRING STREET SILVER SPRING MD 20910
Klein Katherine J director STEINBERG HALL-DIETRICH HALL 3620 LOCUST WALK PHILADELPHIA PA 19104
Giltner Richard director C/O UNITED THERAPEUTICS CORPORTION 1735 CONNECTICUT AVE. NW WASHINGTON DC 20009
Olian Judy D. director 2000 AVENUE OF THE STARS 12TH FL LOS ANGELES CA 90067
Edgemond James officer: CFO and Treasurer 1040 SPRING STREET SILVER SPRING MD 20910
Zaccardelli David officer: EVP & Chief Operating Officer 300 TRI STATE INTERNATIONAL SUITE 272 LINCOLNSHIRE IL 60069
Eli Lilly & Co 10 percent owner LILLY CORPORATE CENTER DROP CODE 1094 INDIANAPOLIS IN 46285
Ferrari John Maxim officer: CFO & Treasurer 1110 SPRING STREET SILVER SPRING MD 20910
Patusky Christopher director
Hicks Henry Beecher Iii director C/O UNITED THERAPEUTICS CORP 1110 SPRING STREET SILVER SPRINGS MD 20910
Gray R Paul director C/O UNITED THERAPEUTICS CORP 1110 SPRING STREET SILVER SPRINGS MD 20910
Dwek Raymond director

United Therapeutics Headlines

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)